Clinical Trials Browser

Terminated × Burkitt Lymphoma × ibritumomab tiuxetan × Clear all

NCT01434472 2021-07-20

High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma

Phase 2 Terminated

20 enrolled 15 charts

Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00036855 2013-01-17

Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma

Phase 1 Terminated

LymphoidSarcoma

Burkitt Lymphoma, Recurrence, Dendritic Cell Sarcoma, Interdigitating